- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01786122
Clinical Trial: Effectiveness and Efficiency of Physical Exercise in Cancer Patients (EFICANCER)
July 22, 2014 updated by: Gonzalo Grandes, Basque Health Service
PHYSICAL EXERCISE TO IMPROVE THE QUALITY OF LIFE OF CANCER PATIENTS DURING TREATMENT PROCESS: EFICANCER STUDY
AIM: To evaluate the effectiveness and efficiency of an innovative exercise program (EP) for patients during treatment for gastrointestinal tumors, breast and non small cells lung cancer, in terms of improved quality of life (QOL), fatigue and functional capacity respect the usual standard treatment (ST).
DESIGN: Pragmatic randomized clinical trial in two parallel groups: EP and ST.
SETTING: 7 Primary Health Centers (PHC) of the redIAPPISCIII, in coordination with oncology services.
PARTICIPANTS: 250 patients with the above tumors, locally advanced or with metastatic disease, in adjuvant treatment, with Performance Status(PS) PS1-PS0.
INTERVENTION: Both groups received standardized usual care.
The EP group will receive, in addition, a nurse supervised exercise program for 2 months in the PHC and a second phase in community facilities during the remaining 10 months.
MEASUREMENTS: The primary outcome measure is the change from baseline in the QOL+66 treatment, as measured by the specific questionnaire for patients with cancer EORTC QLQ-C-30 and Short Form(SF-36) overall.
Secondary: fatigue (FACIT-F), radiological response, functional capacity (6 minutes walking and cardiopulmonary test), muscle strength and progression-free survival and overall.
Predictors and confounders: age, sex, stage and tumor type, histology, treatment.
ANALYSIS: We will compare between groups mean changes from baseline measurement of quality of life questionnaire (QOL) and other variables, on an intention to treat basis, using longitudinal mixed-effects models for repeated measures at 2, 6 and 12 months follow-up.
Cost / effectiveness and cost / incremental utility associated to the program wil be estimated.
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
250
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Bizkaia
-
Bilbao, Bizkaia, Spain, 48014
- Recruiting
- Primary Care Research Unit of Bizkaia
-
Contact:
- ARIETALEANIZBEASCOA MARISOL, NURSE
- Phone Number: 946006637
- Email: MARIASOLEDAD.ARIETALEANIZBEASCOASARABIA@osakidetza.net
-
Contact:
- ARCE ARANA, NURSE
- Phone Number: 946006637
- Email: VERONICA.ARCEARANA@osakidetza.net
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age between 18-70 years
- Diagnosis of digestive system cancer , breast cancer or histologically confirmed NSCLC stage IV Physical Status (PS) 0 or 1.
- First-line chemotherapy treatment for each type of standard tumor
- Adequate renal, liver and blood function.
Exclusion Criteria:
- Brain metastases
- Risk of fracture (bone metastases)
- Unstable heart disease, uncontrolled BP Systolic Blood Pressure((SBP)> 200 or Diastolic Blood Pressure (DBP)> 110), heart failure (NYHA II or greater), constrictive pericarditis
- Other diseases at the discretion of the investigator to be a contraindication for physical exercise.
- Perform regular physical activity (150 minutes / week of moderate or vigorous 75)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Exercise group
supervised exercise program education program on healthy habits Pharmacological treatment and selfcare encouragement
|
Both groups received standardized usual care.
The EP group will receive, in addition, a nurse supervised exercise program for 2 months in the PHC and a second phase in community facilities during the remaining 10 month
education program on healthy habits for 2 months in the PHC and a second phase in community facilities during the remaining 10 months
|
|
No Intervention: control group
Pharmacological treatment and selfcare encouragement.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes in Health Related Quality of Life (EORTC QLQ-C30)
Time Frame: basal,2,6,12 months fllow up
|
basal,2,6,12 months fllow up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
asthenia measurement with FACIT-F (Functional Assessment of Chronic Illness Therapy-Fatigue) questionaire
Time Frame: Basal, 2,6 and12 months
|
Basal, 2,6 and12 months
|
|
Functional Capacity-6 minute Walking test
Time Frame: basal, 2,6 and 12 months
|
basal, 2,6 and 12 months
|
|
cardiorespiratory test
Time Frame: basal, 2, 6 and12 months
|
basal, 2, 6 and12 months
|
|
Changes in Muscular Strenght-Dynamometer
Time Frame: basal, 2,6 nad 12 months
|
basal, 2,6 nad 12 months
|
|
progression-free survival
Time Frame: basal, 2, 6 and 12 months
|
basal, 2, 6 and 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: GRANDES GONZALO, Medicine, Primary Care Research Unit of Bizkaia (Basque Health Service)
- Study Director: ARIETALEANIZBEASCOA MARIA SOLEDAD, NURSE, Primary Care Research Unit of Bizkaia (Basque Health Service)
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2013
Primary Completion (Anticipated)
January 1, 2015
Study Completion (Anticipated)
December 1, 2015
Study Registration Dates
First Submitted
February 5, 2013
First Submitted That Met QC Criteria
February 5, 2013
First Posted (Estimate)
February 7, 2013
Study Record Updates
Last Update Posted (Estimate)
July 23, 2014
Last Update Submitted That Met QC Criteria
July 22, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Skin Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Neoplasms by Site
- Gastrointestinal Diseases
- Breast Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Neoplasms
- Breast Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
Other Study ID Numbers
- EFICANCER PI12/02113
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Digestive System Neoplasms
-
Zhejiang Doer Biologics Co., Ltd.TerminatedMalignant Neoplasm of Digestive SystemChina
-
Suzhou Immunofoco Biotechnology Co., LtdRecruitingAdvanced Digestive System TumorChina
-
The First Affiliated Hospital with Nanjing Medical...Active, not recruitingDigestive System CancerChina
-
Tongji HospitalJiangsu HengRui Medicine Co., Ltd.; Innovent Biologics (Suzhou) Co. Ltd.Not yet recruiting
-
Changhai HospitalShanghai Ultra-T Immune Therapeutics Co. LTDNot yet recruiting
-
Mayo ClinicRecruitingMalignant Digestive System NeoplasmUnited States
-
Mahidol UniversityCompletedDigestive System CancerThailand
-
Innovative Cellular Therapeutics Co., Ltd.Anhui Provincial Cancer HospitalNot yet recruiting
-
Peking UniversityNot yet recruiting
-
Henan Cancer HospitalRecruitingDigestive System TumorsChina
Clinical Trials on Supervised Physical activity
-
AUSL Romagna RiminiFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRecruitingNon-Small Cell Lung CancerItaly
-
University of Illinois at Urbana-ChampaignCompletedQuality of Life | Physical Activity | Cognitive Impairment | Cancer of the ProstateUnited States
-
Centre Hospitalier Universitaire, AmiensCompleted
-
Basque Health ServiceInstituto de Salud Carlos IIICompletedNeoplasms | Quality of Life | Schizophrenia | Physical Activity | COPD | Primary CareSpain
-
UNICANCERCAMI: Sport & CancerActive, not recruitingHome Based Standardised Adapted Physical Activity Programme | Patients Taking Oral Targeted Therapy for Metastatic CancerFrance
-
University of ZurichUniversity Children's Hospital BaselCompletedLate-effects of Childhood CancerSwitzerland
-
European University Miguel de CervantesAsociación de Familiares de Alzheimer de ValladolidCompletedAlzheimer DiseaseSpain
-
University Hospital of FerraraUniversità degli Studi di FerraraCompletedChronic Kidney Disease Stage 5 on DialysisItaly
-
Atlas UniversityCompletedAwareness Training | Prevention/Health PromotionTurkey (Türkiye)